Omicia is unlocking the potential of individualized medicine. Our mission is to help researchers and clinicians understand and apply the most relevant information from next-generation sequencing data, to improve disease management and medical outcomes.
Clinical diagnostic organizations and researchers use our solutions to analyze and derive clinically relevant insights from genomic data. For clinical diagnostic labs, Omicia’s flagship product, Opal Clinical, provides an end-to-end solution for clinical NGS testing, with comprehensive clinical interpretation, fast turnaround time and scalability. Opal Clinical delivers a comprehensive annotation platform, structured workflows and full support for clinical report generation — all within a secure, HIPAA-compliant environment. Omicia’s products are in use at more than 500 world-class academic and clinical institutions worldwide including the UK 100,000 Genomes Project, LabCorp and University of Utah.